Vonjo™ (pacritinib) – New orphan drug approval
February 28, 2022 - CTI BioPharma announced the FDA approval of Vonjo (pacritinib), for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
Top